Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications

Shen, Hong; Li, Rui; Yan, Rong; Zhou, Xia; Feng, Xiaoshan; Zhao, Mengjie; Xiao, Hong

doi:10.1016/j.psychres.2018.02.018

Cited by 49 publications

(47 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta-analysis of statins as adjunctive therapy for schizophrenia included 6 placebo-controlled randomized clinical trials (RCTs) and found a reduction in the Positive and Negative Symptom Scale scores in patients receiving statins for 12 weeks; however, only 169 received active treatment, and the reduction fell below the threshold considered clinically meaningful. 4 Theorized mechanisms for HMG-CoA RI psychiatric action are via anti-inflammatory effects or via increased absorption and central nervous system uptake of antipsychotics. 4 A systematic review and meta-analysis of LTCC antagonists for the treatment of BPD 5 included 2 RCTs of verapamil vs placebo and 4 of verapamil vs lithium for the treatment of mania.…”

Section: Introductionmentioning

confidence: 99%

“… 4 Theorized mechanisms for HMG-CoA RI psychiatric action are via anti-inflammatory effects or via increased absorption and central nervous system uptake of antipsychotics. 4 A systematic review and meta-analysis of LTCC antagonists for the treatment of BPD 5 included 2 RCTs of verapamil vs placebo and 4 of verapamil vs lithium for the treatment of mania. The investigators found no evidence of an effect.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness

et al. 2019

View full text Add to dashboard Cite

Key Points Question Are drugs in common use for physical health problems (hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type calcium channel antagonists, and biguanides) associated with reduced rates of psychiatric hospitalization and self-harm in individuals with serious mental illness? Findings In this series of within-individual cohort studies of 142 691 patients with bipolar disorder, schizophrenia, or nonaffective psychosis, exposure to any of the study drugs was associated with reduced rates of psychiatric hospitalizaiton compared with unexposed periods. Self-harm was reduced in patients with bipolar disorder and schizophrenia during exposure to all study drugs and in patients with nonaffective psychosis taking L-type calcium channel antagonists. Meaning Hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type calcium channel antagonists, and biguanides hold potential as repurposed agents in serious mental illness, and the central nervous system mechanism of action of these drugs requires further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Likewise, Shen et al [97] comprehensively showed beneficial effects of statins on positive and negative symptoms in 6 trials. Considering the mixed and negative results of other trials, further studies to determine effective and safe strategies for the adjunctive use of anti-inflammatory agents in patients with schizophrenia are warranted.…”

Section: Other Agentsmentioning

confidence: 99%

“…In addition, simvastatin also could alleviate cognitive function and had antipsychotic-like effects by modulating muscarinic receptors M1/4, central dopamine receptors D1/2, and the serotonin transporter [93][94][95][96]. A meta-analysis [97] of statin adjunctive therapy for schizophrenia showed statins improved the positive and negative symptom scores of the PANSS in 6 RCTs comprising 339 patients. Especially, only in the simvastatin group (40 mg/day), there was a correlation between statin adjunctive therapy and the reduction in negative symptoms.…”

Section: Statinsmentioning

confidence: 99%

Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing

Hong

Bang

2020

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Schizophrenia is a debilitating psychiatric disorder with a substantial socioeconomic and humanistic burden. Currently available treatment strategies mostly rely on antipsychotic drugs, which block dopaminergic effects in the mesolimbic pathway of the brain. Although antipsychotic drugs help relieve psychotic symptoms, a definitive cure for schizophrenia has yet to be achieved. Recent advances in neuroinflammation research suggest that proinflammatory processes in the brain could cause alterations in neurobehavioral development and increase vulnerability to schizophrenia. With a growing need for novel strategies in the treatment of schizophrenia, it would be meaningful to review the current evidence supporting the therapeutic potential of anti-inflammatory strategies. This review details the key findings of clinical trials that investigate the efficacy of anti-inflammatory agents as adjuvants to antipsychotic treatment. We further discuss the possibilities of repurposing anti-inflammatory agents and developing novel strategies for the treatment of schizophrenia.

show abstract

“…Podobnie istnieją RTC, potwierdzone metaanalizą, wskazujące na możliwość wykorzystania statyn jako terapii dodanej w schizofrenii [38]. Działanie antypsychotyczne wynika prawdopodobnie z właściwości plejotropowych statyn, stwierdzono bowiem związek procesów immunologicznych i zapalnych z wystąpieniem objawów schizofrenii i odpowiedzią na leczenie.…”

Section: Statyny a Choroby Psychiczneunclassified

Analysis of utilization of medication from A02BA and A02BC group – results of the survey study among patients from community pharmacy

Jaworska¹,

Skowron²

2018

Farm Pol.

View full text Add to dashboard Cite

Central nervous system effects of statins: benefit or risk? • 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, more commonly referred to as statins, are principal therapeutic agents for the treatment of dyslipidaemia. and primary and secondary prevention of cardiovascular disease. In addition to lipid-lowering abilities, statins have pleiotropic properties that include antithrombotic, antiinflammatory, antioxidative, immunomodulatory, and antiexcitotoxic effects. These drugs are generally well tolerated and serious adverse events are rare. Both case reports and pharmacovigilance data have demonstrated the occurrence of neuropsychiatric reactions associated with statin treatment, such as memory loss, depression, suicidality, aggression and sleep disturbance. However, over recent years, statins have also been shown to exert neuroprotective effects that might be of therapeutic benefit in neuropsychiatric disorders. In the present paper the statins' effects on the central nervous system are described.

show abstract

Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications

Cited by 49 publications

References 25 publications

Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness

Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness

Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing

Analysis of utilization of medication from A02BA and A02BC group – results of the survey study among patients from community pharmacy

Contact Info

Product

Resources

About